Literature DB >> 16790440

Structure-function relationships in the neuropeptide S receptor: molecular consequences of the asthma-associated mutation N107I.

Virginie Bernier1, Rino Stocco, Michael J Bogusky, Joseph G Joyce, Christine Parachoniak, Karl Grenier, Michael Arget, Marie-Claude Mathieu, Gary P O'Neill, Deborah Slipetz, Michael A Crackower, Christopher M Tan, Alex G Therien.   

Abstract

Neuropeptide S (NPS) and its receptor (NPSR) are thought to have a role in asthma pathogenesis; a number of single nucleotide polymorphisms within NPSR have been shown to be associated with an increased prevalance of asthma. One such single nucleotide polymorphism leads to the missense mutation N107I, which results in an increase in the potency of NPS for NPSR. To gain insight into structure-function relationships within NPS and NPSR, we first carried out a limited structural characterization of NPS and subjected the peptide to extensive mutagenesis studies. Our results show that the NH(2)-terminal third of NPS, in particular residues Phe-2, Arg-3, Asn-4, and Val-6, are necessary and sufficient for activation of NPSR. Furthermore, part of a nascent helix within the peptide, spanning residues 5 through 13, acts as a regulatory region that inhibits receptor activation. Notably, this inhibition is absent in the asthma-linked N107I variant of NPSR, suggesting that residue 107 interacts with the aforementioned regulatory region of NPS. Whereas this interaction may be at the root of the increase in potency associated with the N107I variant, we show here that the mutation also causes an increase in cell-surface expression of the mutant receptor, leading to a concomitant increase in the maximal efficacy (E(max)) of NPS. Our results identify the key residues of NPS involved in NPSR activation and suggest a molecular basis for the functional effects of the N107I mutation and for its putative pathophysiological link with asthma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16790440     DOI: 10.1074/jbc.M603691200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Identification of the first biased NPS receptor agonist that retains anxiolytic and memory promoting effects with reduced levels of locomotor stimulation.

Authors:  Stewart D Clark; Terrence P Kenakin; Steven Gertz; Carla Hassler; Elaine A Gay; Tiffany L Langston; Rainer K Reinscheid; Scott P Runyon
Journal:  Neuropharmacology       Date:  2017-03-03       Impact factor: 5.250

2.  Human Neuropeptide S Receptor Is Activated via a Gαq Protein-biased Signaling Cascade by a Human Neuropeptide S Analog Lacking the C-terminal 10 Residues.

Authors:  Yuan Liao; Bin Lu; Qiang Ma; Gang Wu; Xiangru Lai; Jiashu Zang; Ying Shi; Dongxiang Liu; Feng Han; Naiming Zhou
Journal:  J Biol Chem       Date:  2016-02-10       Impact factor: 5.157

3.  Abnormal response to stress and impaired NPS-induced hyperlocomotion, anxiolytic effect and corticosterone increase in mice lacking NPSR1.

Authors:  Hongyan Zhu; Melissa K Mingler; Melissa L McBride; Andrew J Murphy; David M Valenzuela; George D Yancopoulos; Michael T Williams; Charles V Vorhees; Marc E Rothenberg
Journal:  Psychoneuroendocrinology       Date:  2010-02-19       Impact factor: 4.905

4.  Importance of extracellular loop one of the neuropeptide S receptor for biogenesis and function.

Authors:  Stewart D Clark; Ha T Tran; Joanne Zeng; Rainer K Reinscheid
Journal:  Peptides       Date:  2009-10-27       Impact factor: 3.750

5.  Selective breeding for high anxiety introduces a synonymous SNP that increases neuropeptide S receptor activity.

Authors:  David A Slattery; Roshan R Naik; Thomas Grund; Yi-Chun Yen; Simone B Sartori; Andrea Füchsl; Beate C Finger; Betina Elfving; Uwe Nordemann; Remo Guerrini; Girolamo Calo; Gregers Wegener; Aleksander A Mathé; Nicolas Singewald; Ludwig Czibere; Rainer Landgraf; Inga D Neumann
Journal:  J Neurosci       Date:  2015-03-18       Impact factor: 6.167

6.  Analysis of neuropeptide S receptor gene (NPSR1) polymorphism in rheumatoid arthritis.

Authors:  Mauro D'Amato; Marco Zucchelli; Maria Seddighzadeh; Francesca Anedda; Staffan Lindblad; Juha Kere; Lars Alfredsson; Lars Klareskog; Leonid Padyukov
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

7.  Neuropeptide S receptor induces neuropeptide expression and associates with intermediate phenotypes of functional gastrointestinal disorders.

Authors:  Michael Camilleri; Paula Carlson; Alan R Zinsmeister; Sanna McKinzie; Irene Busciglio; Duane Burton; Marco Zucchelli; Mauro D'Amato
Journal:  Gastroenterology       Date:  2009-09-02       Impact factor: 22.682

8.  Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists.

Authors:  Remo Guerrini; Valeria Camarda; Claudio Trapella; Girolamo Caló; Anna Rizzi; Chiara Ruzza; Stella Fiorini; Erika Marzola; Rainer K Reinscheid; Domenico Regoli; Severo Salvadori
Journal:  J Med Chem       Date:  2009-07-09       Impact factor: 7.446

9.  Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice.

Authors:  A Rizzi; R Vergura; G Marzola; C Ruzza; R Guerrini; S Salvadori; D Regoli; G Calo
Journal:  Br J Pharmacol       Date:  2008-03-31       Impact factor: 8.739

10.  In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S.

Authors:  Valeria Camarda; Anna Rizzi; Chiara Ruzza; Silvia Zucchini; Giuliano Marzola; Erika Marzola; Remo Guerrini; Severo Salvadori; Rainer K Reinscheid; Domenico Regoli; Girolamo Calò
Journal:  J Pharmacol Exp Ther       Date:  2008-10-29       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.